Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights May 03, 2018
Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission Apr 20, 2018
Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting Apr 18, 2018
Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights Mar 29, 2018
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol Mar 28, 2018
Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis Mar 27, 2018
Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301 Mar 21, 2018
Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis Mar 21, 2018
